Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raynier Devillier

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
Experimental Hematology|November 21, 2017
T-cell-replete haploidentical transplantation in acute myeloid leukemiaLuca Castagna, Raynier Devillier, Norbert Vey, et al.
Bone Marrow Transplantation|May 8, 2026
Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomesMingyang Wang, Jieya Luo, Didier Blaise, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2017
Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical casesAudrey Monneur, Jilliana Monnier, Caroline Gaudy-Marqueste, et al.
Medecine Sciences : M/S|July 3, 2020
[PD-L1 glycosylation under the spotlights]Daniel Olive, Anne-Sophie Chrétien, Raynier Devillier, et al.
Journal of Leukocyte Biology|September 29, 2020
Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapyRaynier Devillier, Anne-Sophie Chrétien, Thomas Pagliardini, et al.
Journal of Hematology & Oncology|March 23, 2012
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseasesVéronique Gelsi-Boyer, Mandy Brecqueville, Raynier Devillier, et al.
British Journal of Clinical Pharmacology|November 20, 2024
Adaptive dosing of high-dose busulfan in real-world adult patients undergoing haematopoietic cell transplant conditioningDorian Protzenko, Benjamin Bouchacourt, Laure Carriat, et al.
BMC Cancer|July 25, 2012
Myeloid malignancies: mutations, models and managementAnne Murati, Mandy Brecqueville, Raynier Devillier, et al.
Frontiers in Immunology|November 30, 2016
Manufacturing Natural Killer Cells as Medicinal ProductsChristian Chabannon, Bechara Mfarrej, Sophie Guia, et al.
American Journal of Hematology|April 27, 2012
Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutationsRaynier Devillier, Véronique Gelsi-Boyer, Mandy Brecqueville, et al.
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
Experimental Hematology|November 21, 2017
T-cell-replete haploidentical transplantation in acute myeloid leukemiaLuca Castagna, Raynier Devillier, Norbert Vey, et al.
Bone Marrow Transplantation|May 8, 2026
Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomesMingyang Wang, Jieya Luo, Didier Blaise, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2017
Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical casesAudrey Monneur, Jilliana Monnier, Caroline Gaudy-Marqueste, et al.
Medecine Sciences : M/S|July 3, 2020
[PD-L1 glycosylation under the spotlights]Daniel Olive, Anne-Sophie Chrétien, Raynier Devillier, et al.
Journal of Leukocyte Biology|September 29, 2020
Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapyRaynier Devillier, Anne-Sophie Chrétien, Thomas Pagliardini, et al.
Journal of Hematology & Oncology|March 23, 2012
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseasesVéronique Gelsi-Boyer, Mandy Brecqueville, Raynier Devillier, et al.
British Journal of Clinical Pharmacology|November 20, 2024
Adaptive dosing of high-dose busulfan in real-world adult patients undergoing haematopoietic cell transplant conditioningDorian Protzenko, Benjamin Bouchacourt, Laure Carriat, et al.
BMC Cancer|July 25, 2012
Myeloid malignancies: mutations, models and managementAnne Murati, Mandy Brecqueville, Raynier Devillier, et al.
Frontiers in Immunology|November 30, 2016
Manufacturing Natural Killer Cells as Medicinal ProductsChristian Chabannon, Bechara Mfarrej, Sophie Guia, et al.
American Journal of Hematology|April 27, 2012
Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutationsRaynier Devillier, Véronique Gelsi-Boyer, Mandy Brecqueville, et al.
Pageof 12